Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Brivaracetam Oral Solution
NCT06762743Phase 1Enrolling by invitation
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brivaracetam in epilepsy (2 arms), sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 2 weeks, Area Under the Plasma Concentration-Time Curve from Time 0 to Last Measurable Concentration at 2 weeks and 1 more. Started Oct 2024; status: enrolling by invitation.
02
Drugs
brivaracetam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06762743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762743.